Cambridge, USA-based precision allosteric therapeutics biotech Atavistik Bio has announced the closing of a $40 million ...

Swiss pharma Roche (ROG: SIX) reported positive Phase II results for its investigational amylin analog petrelintide, showing meaningful weight loss and a placebo-like tolerability profile in people ...

US drugmaker Vertex Pharmaceuticals today announced data from a Phase IV study of Journavx (suzetrigine), a prescription ...

Swedish specialty pharma Orexo is reorganizing its management team as it pivots away from direct US commercialization ...

The Accelerating Clinical Trials in the EU (ACT EU) initiative has published a draft guidance document outlining how clinical ...

Shares of US clinical-stage biotech Tenaya Therapeutics closed up more than 40% at $0.82 yesterday following its announcement of a potentially lucrative collaboration.

Germany’s Merck KGaA reported broadly stable full-year 2025 results, with modest top-line pressure from currency headwinds ...

Canada based clinical-stage pharma Helus Pharma today announced top-line results from a Phase II signal detection study ...

Swiss drugmaker Roche (ROG: SIX) has released findings from a global survey suggesting that the unpredictability of diabetes ...

A pre-clinical biopharmaceutical company dedicated to precision cardiology through targeted RNA therapeutics designed to ...

I've worked with pharmaceutical companies for years, and one pattern keeps repeating: the most significant environmental, health, and safety (EHS) risks are rarely dramatic. They sit in routine ...